Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Universität Duisburg-Essen
Patients who have progressed after first-line treatment with afatinib as first tyrosine kinase inhibitor (TKI) will be screened while they are receiving second-line (induction) treatment consisting of cisplatin / carboplatin plus pemetrexed given in 21-day cycles. Patients who do not progress (i.e. complete or partial response, or stable disease - CR, PR or SD) after completion of at least three and not more than four chemotherapy cycles will be randomized (1:1 ratio) to receive maintenance therapy with either afatinib (40 mg/d or last tolerated dose during first-line treatment with afatinib as first TKI) or pemetrexed (500 mg/m2 or 375 mg/m2 if dose reduction was required every 21 days) until disease progression or treatment discontinuation because of patient decision or toxicity.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Participation in the AIO-TRK-0114 (MARBLE) study (EudraCT-No. 2014-001983-36)